NORTH AMERICA
Media Center

Macrocyclics to Collaborate with Roche on Molecular Innovation for Nuclear Medicine

Press Release

May 22, 2013

Dallas, TX, May 22, 2013 - After the successful completion of their first 2012 collaboration, Macrocyclics (an AREVA Med company) announced today a new collaborative research agreement with Roche for the continued development of novel chelating agents designed specifically by Macrocyclics for Roche’s applications.

The new project will build on established expertise related to lead-212 (212Pb) and novel chelate architecture for radioimmunotherapy.

“We are privileged to be working with the world leader in oncology and antibody technology and are excited to contribute in the development of powerful new therapies based on lead-212” said Garry Kiefer, CEO of Macrocyclics.

The high level of synergy between the two organizations is expected to speed up the clinical development process.

Contacts

Macrocyclics
Garry Kiefer
T: +1 972 250 2248
F: +1 972 250 2245
info@macrocyclics.com

AREVA Med
Alison Bedford
T: +1 301 841 1673
F: +1 434 382 4250
alison.bedford@areva.com

More About Macrocyclics

Macrocyclics is the global leader in high performance chelating agent technologies for medicine since 1995.  Our team at Macrocyclics is dedicated to providing clients with both established and innovative chelating agents and services to meet the challenges of molecular imaging and nuclear medicine. www.macrocyclics.com

More About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

More About AREVA Med

AREVA Med is an AREVA subsidiary specializing in the development of innovative therapies to fight cancer. AREVA Med has developed new processes for producing high purity lead-212 (²¹²Pb), a rare radioactive isotope that is currently at the heart of promising nuclear medicine research.  In 2011, AREVA Med acquired Macrocyclics, the global leader in high performance chelating agent technology.  AREVA Med is also associated with world-class scientific partners, such as the National Cancer Institute (NCI), the University of Alabama at Birmingham (UAB), and the French National Institute of Health and Medical Research (Inserm). In 2012, AREVA Med and Roche entered a strategic alliance to create novel advanced alpha radioimmunotherapy treatments to target and kill certain very aggressive types of cancer cells.  For more information: http://arevamed.areva.com/ or www.targetedtrials.com.

Join the Conversation
@AREVAus AREVAinc on Facebook AREVAinc on YouTube AREVA on LinkedIn